Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Apixaban geassocieerd met lager risico op posttrombotisch syndroom na diepveneuze trombose
apr 2026 | Benigne hematologie